Aa Lettergrootte
16

MMRVAXPRO (BOF/MAZELEN/RUBELLAVACCIN)

  Attention: The results shown, apply for the ATC-group of drugs to which MMRVAXPRO (BOF/MAZELEN/RUBELLAVACCIN) belongs. Click here for a complete overview of these drugs.
The below shown drugs belong to the same group (based on ATC code).

ATC-code Drug Form
J07BD52 MMRVAXPRO (BOF/MAZELEN/RUBELLAVACCIN) Injectie
J07BD52 MMRVAXPRO (BOFVACCIN/MAZELENVACCIN/RUBELLAVACCIN) Poeder voor injectie
J07BD52 PRIORIX () Injectie

Click for more information about:

Publications by Lareb

Publications, both in English and in Dutch, by the Netherlands Pharmacovigilance Centre Lareb

# Author(s) Title Magazine Year Volume Download
1 W. J. A. Hilgersom · A. A. W. van Boekel · H. C. Rümke Aanvallen na vaccinatie van zuigelingen en peuters Tijdschr Jeugdgezondheidszorg 2017 49:2–7
2 Erp-van Boekel, A.A.W. van Ataxie meest gemeld bij anti-epileptica en vaccins PW 2019 154(45):16-17
3 Marcy S.M., Kohl K.S., Labadie J. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis and presentation Vaccine 2004 22(5-6):551-556
4 Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, Hansen J, Labadie J, Lee L, Martin BL, O'Brien K, Rothstein, Vermeer P Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation Vaccine 2004 22(5-6):551-556
5 Steenvoorden, G. Gemelde bijwerkingen ’14 en ’15 van reizigersvaccins en malariaprofylaxe bij Bijwerkingencentrum Lareb LCR Update 2016 18(3):6-7
6 Boekel, A. van, Härmark, L., Puijenbroek, E.P. van Latency period of crying following vaccination with MMR vaccine. What do spontaneous AEFI-reports show? Drug Safety 2017 2017(40):981-982
7 Labadie J., Grootheest van A.C. Meldingen van bijwerkingen van vaccins bij het Nederlands Bijwerkingen Centrum Lareb in 2004-2006 NTVG 2007 151(49):2738-2742
8 Labadie J., Vermeer-de Bondt P.E. Passive surveillance of adverse events following immunization in the Netherlands (abstract) PEDS 2002 11(2):S287
9 Labadie J. Vakcinas Cito (Latvian Drug Bulletin) 2005 5(17):4
Signals

Signals as submitted to Lareb to the Dutch Medicines Evaluation Board. Some of the articles are in Dutch only.

# Title Year Download
1 M-M-RVAXPRO and crying 2016
Overview of reports submitted to Lareb

To ensure a correct interpretation of the results, the data shown may only be used for publications or other media after consulting Lareb. Please read the disclaimer.

The reports shown on this website were received directly by the Netherlands Pharmacovigilance Centre Lareb. If you enter a brand name or generic name, all reports of products will be shown that contain the corresponding active substance. The selection that is shown is based on the ATC classification system of the World Health Organization.

The fact that a possible side effect of a drug or vaccine is reported, does not imply that the reported symptoms are actually caused by the drug or vaccine. Since the aim of a voluntary reporting centre is to detect new adverse drug reactions, we ask healthcare professionals and consumers to report suspicions of ADRs, even if the causal relationship has not been proven.

One single report may refer to multiple ADRs For this reason, the number of reports may be higher than the number of reports shown in the overview.

The number of reports shown does not necessarily reflect the actual change for an ADR to occur. It is therefore not possible to calculate an incidence rate of these ADRs based on these data.

Most recent update: 2/18/2020.

MAZELEN MET BOF EN RUBELLA, LEVEND VERZWAKT

Number of reports 3,417
Serious 460
Gender
Male
Female
Unknown
1,784
(52%)
1,628
(48%)
5
(0%)
Age
 
Year received
Calender year of reporting.
 
Year ADR
Calender year in which the possible ADR occured. If more events have been reported, the year in which the first event occurred is shown. Before 2002 the date, on which the report was received, was noted instead of the date of occurrence of the possible adverse drug reaction. For these reports the year in which the reaction actually occurred is not always known.
 
Reporter
 

Overview of reported side effects

Click on a side effect for more specific information

Blood and lymphatic system : 115
Abdominal lymphadenopathy : 1
Autoimmune haemolytic anaemia : 1
Anaemia : 3
Glucose-6-phosphate dehydrogenase deficiency : 1
Immune thrombocytopenic purpura : 20
Lymphadenitis : 6
Thrombocytopenia : 11
Thrombocytopenic purpura : 12
Lymphadenopathy : 60
Cardiac : 62
Cyanosis : 56
Palpitations : 1
Arrhythmia : 1
Oedema peripheral : 1
Tachycardia : 3
Ear and labyrinth : 15
Deafness : 2
Ear pain : 10
Otorrhoea : 1
Hyperacusis : 1
Auricular swelling : 1
Endocrine system : 1
Hypothyroidism : 1
Eye : 153
Exophthalmos : 1
Eye movement disorder : 5
Dry eye : 1
Diplopia : 2
Visual impairment : 5
Eye pruritus : 2
Photophobia : 2
Ocular discomfort : 1
Gaze palsy : 68
Conjunctivitis : 15
Eye discharge : 6
Eye irritation : 2
Eye inflammation : 9
Eye pain : 3
Eye swelling : 12
Excessive eye blinking : 1
Eyelid ptosis : 1
Conjunctival hyperaemia : 4
Ocular hyperaemia : 3
Strabismus : 1
Lacrimation increased : 4
Mydriasis : 1
Vision blurred : 1
Swelling of eyelid : 3
Gastrointestinal : 779
Gastrointestinal disorder : 6
Abnormal faeces : 6
Aphthous ulcer : 4
Anorectal discomfort : 1
Oral mucosal blistering : 2
Haematemesis : 1
Diarrhoea haemorrhagic : 1
Retching : 5
Vomiting : 346
Glossodynia : 2
Abdominal discomfort : 3
Abdominal pain : 74
Diarrhoea : 157
Intussusception : 1
Dysphagia : 5
Tongue ulceration : 1
Lip dry : 1
Lip blister : 2
Lip swelling : 7
Gastrointestinal pain : 3
Nausea : 101
Constipation : 3
Stomatitis : 5
Gingivitis : 1
Breath odour : 2
Oral mucosal eruption : 4
Oral papule : 1
Abdominal pain upper : 10
Oral pain : 6
Vomiting projectile : 1
Mucous stools : 1
Gingival bleeding : 1
Tongue coated : 1
Tongue blistering : 1
Tongue discomfort : 1
Parotid gland enlargement : 4
Salivary hypersecretion : 4
Flatulence : 2
Faeces soft : 1
Mouth swelling : 1
General disorders and administr. Site : 3479
Injection site abscess : 1
General physical health deterioration : 1
Sense of oppression : 3
Injection site haemorrhage : 1
Developmental regression : 1
Enanthema : 1
Vaccination site erythema : 4
Localised oedema : 1
Drug ineffective : 10
Adverse drug reaction : 1
Injection site movement impairment : 1
Feeling abnormal : 4
Feeling of body temperature change : 2
Influenza like illness : 14
Growth retardation : 1
Feeling hot : 1
Feeling cold : 2
Hyperpyrexia : 138
Injection site dermatitis : 1
Injection site cellulitis : 1
Injection site haematoma : 19
Injection site infection : 2
Injection site bruising : 4
Injection site hypersensitivity : 1
Injection site urticaria : 2
Injection site induration : 24
Injection site discolouration : 5
Injection site vesicles : 6
Injection site warmth : 61
Injection site pruritus : 23
Hangover : 1
Pyrexia : 1,856
Chills : 38
Asthenia : 16
Injection site scar : 1
Local reaction : 1
Gait disturbance : 35
Malaise : 238
Mobility decreased : 3
Multiple organ dysfunction syndrome : 1
Injection site nodule : 5
Axillary mass : 1
Axillary pain : 6
Chest discomfort : 1
Injection site discomfort : 5
Inflammation : 81
Injection site inflammation : 190
Pain : 106
Injection site pain : 158
Injection site reaction : 8
Injection site erythema : 112
Foaming at mouth : 1
Lethargy : 1
Injection site abscess sterile : 2
Extensive swelling of vaccinated limb : 32
Vaccination site inflammation : 1
Vaccination site pain : 1
Fall : 2
Hyperthermia : 1
Injected limb mobility decreased : 17
Fatigue : 85
Condition aggravated : 1
Developmental delay : 2
Vaccination site warmth : 1
Sudden infant death syndrome : 2
Disease recurrence : 1
Swelling : 32
Vaccination site swelling : 1
Injection site swelling : 97
Hepatobiliary : 3
Hepatic function abnormal : 1
Hepatosplenomegaly : 1
Hepatitis : 1
Immune system : 13
Autoimmune disorder : 1
Hypersensitivity : 9
Food allergy : 3
Infections and infestations : 536
Abscess : 7
Peritonsillar abscess : 1
Vaccination site abscess : 1
Abscess of salivary gland : 1
Meningitis bacterial : 2
Pneumonia bacterial : 1
Bacteraemia : 1
Cystitis : 1
Mumps : 7
Upper respiratory tract infection : 12
Respiratory tract infection : 13
Bronchitis : 1
Gastroenteritis : 11
Candida infection : 1
Cellulitis : 1
Pharyngitis : 22
Gastroenteritis viral : 1
Herpes zoster : 2
Influenza : 3
Hand-foot-and-mouth disease : 1
Meningitis : 1
Meningitis pneumococcal : 1
Skin infection : 2
Infection : 6
Ear infection : 22
Febrile convulsion : 219
Herpes simplex : 1
Laryngitis : 1
Pneumonia : 13
Respiratory tract infection bacterial : 1
Lymphadenitis bacterial : 1
Lymph node abscess : 2
Gastrointestinal infection : 5
Measles : 12
Otitis media : 43
Nasopharyngitis : 64
Osteomyelitis : 1
Pyelonephritis : 3
Sialoadenitis : 2
Orchitis : 4
Eye infection : 1
Oral herpes : 1
Otitis media acute : 1
Injection site pustule : 1
Rubella : 3
Sepsis : 3
Parotitis : 12
Streptococcal infection : 1
Subglottic laryngitis : 5
Gianotti-Crosti syndrome : 1
Urinary tract infection : 1
Varicella zoster virus infection : 1
Viral infection : 2
Vulvovaginal candidiasis : 1
Vulvovaginal mycotic infection : 2
Varicella : 3
Molluscum contagiosum : 1
Kawasaki's disease : 2
Injury and poisoning : 28
Blister : 15
Fracture : 1
Joint dislocation : 2
Concussion : 2
Skin abrasion : 2
Hypothermia : 2
Medication error : 2
Metal poisoning : 1
Wound : 1
Investigations : 105
Respiratory rate increased : 1
Electroencephalogram abnormal : 3
Blood urine present : 1
Blood pressure decreased : 1
Red blood cell sedimentation rate increased : 2
Weight decreased : 4
Blood glucose increased : 1
Heart rate irregular : 1
Heart rate increased : 1
Skin turgor decreased : 1
Body temperature abnormal : 1
Body temperature increased : 55
Body temperature decreased : 20
C-reactive protein increased : 11
Body temperature fluctuation : 1
Oxygen saturation abnormal : 1
Metabolism and nutrition : 287
Diabetes mellitus : 6
Food refusal : 1
Weight gain poor : 1
Hypophagia : 9
Hypoglycaemia : 2
Lactose intolerance : 1
Poor feeding infant : 6
Increased appetite : 1
Type 1 diabetes mellitus : 2
Dehydration : 12
Polydipsia : 1
Oligodipsia : 24
Decreased appetite : 219
Fluid intake reduced : 1
Food intolerance : 1
Musculoskeletal and connective tissue : 231
Arthropathy : 1
Arthritis : 14
Polyarthritis : 2
Arthralgia : 29
Joint stiffness : 1
Growing pains : 1
Juvenile idiopathic arthritis : 3
Musculoskeletal discomfort : 5
Neck pain : 6
Synovitis : 1
Spinal osteoarthritis : 1
Peripheral swelling : 6
Pain in extremity : 33
Pain in jaw : 1
Polymyalgia rheumatica : 1
Limb discomfort : 6
Rheumatoid arthritis : 1
Back pain : 2
Musculoskeletal stiffness : 14
Myalgia : 93
Muscle spasms : 4
Muscular weakness : 6
Neoplasms : 3
Haemangioma : 1
Neuroblastoma : 1
Lymphocytic leukaemia : 1
Nervous system : 1232
Disturbance in attention : 5
Facial paralysis : 1
Areflexia : 1
Ataxia : 6
Atonic seizures : 1
Chorea : 1
Loss of consciousness : 133
Haemorrhage intracranial : 1
Burning sensation : 1
Hypotonic-hyporesponsive episode : 13
Cerebellar ataxia : 2
Drop attacks : 1
Dizziness : 68
Dyskinesia : 2
Dysstasia : 1
Hypotonia : 77
Epilepsy : 7
Balance disorder : 4
Syncope : 120
Focal dyscognitive seizures : 1
Hemiparesis : 1
Paresis : 1
Memory impairment : 1
Amnesia : 1
Guillain-Barre syndrome : 3
Encephalopathy : 2
Encephalitis : 4
Headache : 317
Hypersomnia : 7
Intellectual disability : 1
Trismus : 3
Drooling : 35
Migraine with aura : 1
Meningism : 2
Unresponsive to stimuli : 4
Muscle contractions involuntary : 2
Psychomotor hyperactivity : 8
Hyperaesthesia : 1
Petit mal epilepsy : 1
Postictal state : 10
Presyncope : 12
Psychomotor skills impaired : 4
Sensory integrative dysfunction : 1
Poor quality sleep : 16
Somnolence : 87
Taste disorder : 1
Infantile spasms : 1
Myoclonus : 20
Speech disorder developmental : 3
Dysphonia : 2
Sensory disturbance : 2
Paraesthesia : 4
Dystonia : 1
Seizure : 128
Tonic convulsion : 1
Slow response to stimuli : 1
Tremor : 3
Fontanelle bulging : 1
Hypertonia : 45
Paralysis : 1
Depressed level of consciousness : 34
Hypoaesthesia : 1
Status epilepticus : 11
Nervous system disorder : 1
Product issues : 2
Product complaint : 2
Psychiatric : 950
Abnormal behaviour : 31
Abnormal dreams : 1
Attention deficit/hyperactivity disorder : 1
Lack of spontaneous speech : 1
Aggression : 4
Anxiety : 6
Apathy : 14
Autism spectrum disorder : 16
Breath holding : 11
Daydreaming : 1
Delirium febrile : 10
Depressed mood : 2
Derealisation : 1
Disorganised speech : 1
Dissociative disorder : 1
Eating disorder : 2
Emotional distress : 1
Affect lability : 1
Behaviour disorder : 7
Hallucination, visual : 2
Hallucination : 3
Head banging : 7
Hallucination, auditory : 1
Crying : 543
Delirium : 3
Listless : 140
Nightmare : 1
Agitation : 3
Panic attack : 1
Irritability : 9
Mental disorder : 1
Psychomotor retardation : 1
Restlessness : 11
Screaming : 3
Sleep disorder : 14
Insomnia : 61
Social avoidant behaviour : 2
Somnambulism : 1
Speech sound disorder : 1
Staring : 17
Mood swings : 1
Stereotypy : 2
Disturbance in social behaviour : 1
Tic : 2
Euphoric mood : 1
Confusional state : 3
Anger : 1
Nervousness : 2
Renal and urinary tracts : 5
Incontinence : 2
Ketonuria : 1
Pollakiuria : 1
Oliguria : 1
Reproductive system and breasts : 6
Scrotal swelling : 1
Genital rash : 1
Epididymitis : 1
Testicular pain : 1
Scrotal oedema : 1
Gynaecomastia : 1
Respiratory and thoracic : 283
Apnoea : 26
Respiratory distress : 2
Respiratory arrest : 1
Respiration abnormal : 43
Apparent life threatening event : 2
Asphyxia : 1
Asthma : 6
Epistaxis : 12
Cyanosis central : 11
Pharyngeal swelling : 1
Cough : 75
Stridor : 2
Interstitial lung disease : 1
Dyspnoea : 40
Rhinorrhoea : 13
Respiratory disorder : 2
Respiratory tract irritation : 1
Neonatal hypoxia : 1
Nasal discomfort : 1
Nasal oedema : 1
Nasal congestion : 3
Sneezing : 1
Rhinitis : 3
Oropharyngeal discomfort : 2
Oropharyngeal pain : 20
Wheezing : 1
Productive cough : 3
Tachypnoea : 2
Sputum increased : 3
Tonsillar hypertrophy : 3
Skin and subcutaneous tissue : 1536
Acute haemorrhagic oedema of infancy : 1
Dermatitis allergic : 2
Angioedema : 21
Dry skin : 6
Eczema : 66
Erythema of eyelid : 1
Exfoliative rash : 2
Urticaria : 124
Urticaria vesiculosa : 1
Generalised erythema : 1
Face oedema : 2
Alopecia : 2
Skin warm : 43
Lichen planus : 1
Skin erosion : 1
Skin odour abnormal : 1
Skin irritation : 1
Skin lesion : 1
Dermatitis : 1
Dermatitis bullous : 1
Rash : 504
Rash maculo-papular : 45
Rash morbilliform : 62
Rash papular : 63
Rash vesicular : 20
Skin discolouration : 11
Injection site rash : 15
Intertrigo : 1
Pruritus : 73
Rash pruritic : 42
Contusion : 1
Lip discolouration : 1
Dermatitis diaper : 1
Mechanical urticaria : 1
Purpura : 1
Night sweats : 1
Nail disorder : 1
Eyelid oedema : 2
Hypersensitivity vasculitis : 1
Hyperhidrosis : 18
Papule : 5
Perioral dermatitis : 1
Pigmentation disorder : 1
Pruritus generalised : 2
Petechiae : 24
Rash pustular : 4
Pyogenic granuloma : 1
Rash generalised : 109
Photosensitivity reaction : 1
Rash erythematous : 58
Erythema : 28
Urticaria chronic : 1
Skin exfoliation : 3
Rash macular : 106
Swelling face : 35
Cold sweat : 14
Social circumstances : 1
Educational problem : 1
Vascular : 191
Pallor : 159
Haematoma : 7
Cardiovascular insufficiency : 1
Cerebral ischaemia : 1
Raynaud's phenomenon : 1
Circulatory collapse : 5
Henoch-Schonlein purpura : 4
Cerebral haemorrhage : 1
Peripheral coldness : 3
Flushing : 3
Poor peripheral circulation : 1
Vasodilatation : 5
Overview of reports submitted to EMA
All reports submitted to EMA can be found here.
Overview of reports submitted to World Health Organization

VigiBase® data

This data is sourced from VigiBase, the World Health Organization’s (the “WHO”) global database for suspected adverse drug reactions “ADRs”, maintained by Uppsala Monitoring Centre (“UMC”). UMC is the WHO Collaborating Centre for International Drug Monitoring based in Uppsala, Sweden providing scientific leadership and operative support to the WHO Program for International Drug Monitoring (www.who-umc.org).

The data contains reports of suspected ADRs, so called Individual Case Safety Reports (ICSRs), collected by national drug authorities in over 120 countries and span over more than 100 000 different medicinal products. Thus, this database is only a repository of ICSRs provided for VigiBase, and shall not be considered as a systematic register of ADRs that have occurred or may occur.

The volume of ICSRs for a particular medicinal product may be influenced by many different factors, including but not limited to the extent of use of the product, publicity and the nature of the reactions. No information is provided on the number of patients exposed to a particular product, and it is therefore, based on the ICSRs, not possible to calculate frequency of any ADR. Moreover, collection of data is, due to e.g. differing national legislation and policies, heterogeneous between different countries. For these reasons, any interpretation of ADR data, and particularly those based on comparisons between various medicinal products, may be misleading.

Information on a suspected ADR should not be interpreted as meaning that the medicinal product in question, or the active substance(s), generally causes the observed effect or is unsafe to use. Any robust conclusion with regard to benefits and risks of a specific medicinal product always requires detailed evaluation and scientific assessment of all available data. The balance between benefit and risk of a specific medicinal product also varies between individual patients.

If you think that you may be experiencing a side-effect from a medicinal product, please seek advice from a health professional as soon as possible. Never stop or change the dose for prescription medicines without consulting your physician.

About the release of this data:
UMC takes great care to ensure that the data contained herein is an accurate record of data collected by the national drug authorities and transmitted to UMC. UMC does, however, not guarantee, warrant or make any representation whatsoever regarding the data contained herein, including but not limited to guarantees, warranties or representations of accuracy, reliability, completeness, currency, suitability, fitness or usefulness for any particular purpose or with respect to non-infringement of any third-party rights. In no event shall UMC be liable for any loss, damage, cost or other expense whatsoever (whether direct, indirect, punitive, incidental, special or consequential) arising out of or in any way connected with the use of or reference to any data contained herein. In no event shall UMC be liable other than i) under Swedish substantive law and ii) subject to the courts of Sweden with the district court of Uppsala as first instance.

MAZELEN MET BOF EN RUBELLA, LEVEND VERZWAKT

Number of reports 0

Overview of reported side effects

No information available.
Related drugs and vaccines
If you want to search for related substances, you can choose from the list presented here.

No information available.